Erasca to Present at the Guggenheim Healthcare Talks 2022 Oncology Day
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company, announced its participation in the Guggenheim Healthcare Talks 2022 Oncology Day. The event, featuring CEO Jonathan E. Lim and CFO David M. Chacko, will take place in a virtual format on February 10, 2022, at 2:30 PM ET. The company will also engage in one-on-one investor meetings. A live webcast will be available at Erasca.com/events, with an archived replay for 30 days afterward. Erasca focuses on therapies for RAS/MAPK pathway-driven cancers.
Details
News Market Reaction – ERAS
The recorded move for ERAS in the trading session of this news was +0.45%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Guggenheim Healthcare Talks 2022 Oncology Day. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer, will represent Erasca in a virtual fireside chat beginning at 2:30 PM Eastern Time on Thursday, February 10, 2022. The company will also participate in one-on-one investor meetings.
A live webcast of the event will be available online at Erasca.com/events. An archived replay of the event will be available for 30 days following the webcast at Erasca.com/events.
About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled what we believe to be the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
Source: Erasca, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.